Key result
Warfarin discontinuation linked to large left atrial thrombus within 8 days in bioprosthetic mitral stenosis.
Why the study?
Current guidelines do not recommend anticoagulation beyond 6 months after bioprosthetic valve replacement without a separate indication, prompting a review of indications and comorbidities affecting anticoagulation decisions.
Case Report (n=1)
No
Discontinuation of warfarin in a patient with severe bioprosthetic mitral stenosis and vascular comorbidities led to rapid left atrial thrombus formation, highlighting the potential need for individualized anticoagulation strategies beyond standard guidelines.
Answers are grounded in this paper and cite their sources.
Case discussion of extended anticoagulation post-bioprosthetic MVR raises questions about current guidelines; leaves open need for prospective trials before practice change.
BACKGROUND: Mitral valve stenosis can be a highly symptomatic condition with significant complications if left untreated. In such cases, mitral valve replacement with a bioprosthetic or mechanical valve may be a viable solution to prevent progressive disease. Current guidelines do not recommend continued anticoagulation beyond 6 months for patients who have undergone bioprosthetic valve replacement without a separate indication for anticoagulation. With this case discussion we aim to 1) Review the current indications for anticoagulation for bioprosthetic mitral valves in patients without atrial fibrillation and 2) Discuss the constellation of comorbidities that may affect the decision to begin anticoagulation therapy. CASE PRESENTATION: We present a case describing a 55-year-old male with end-stage renal disease, coronary artery disease with coronary artery bypass graft surgery, and bioprosthetic mitral valve replacement 2 years prior with rapid degeneration of the replaced valve and on warfarin without a clear indication for anticoagulation. The patient was admitted for symptomatic, severe mitral stenosis and consideration of transcatheter mitral valve-in-valve replacement. During hospital admission, warfarin was discontinued and replaced with prophylactic anticoagulation. However, 8 days after warfarin cessation an intraoperative transesophageal echocardiography revealed a newly developed large left atrial thrombus leading to cancellation of the planned operation. CONCLUSIONS: This patient developed a left atrial thrombus after discontinuing warfarin in the setting of rapidly deteriorating bioprosthetic valve stenosis and vascular comorbidities. The decision to discontinue warfarin was made in concordance with current guidelines, which do not indicate systemic anticoagulation post 3-6 months after bioprosthetic valve replacement without separate indication for anticoagulation. This case identifies the need to investigate rebound hypercoagulability and further risk stratify comorbidities which may independently increase the risk of clot formation in the setting of severe mitral valve stenosis.
No takes yet. Share an insight, caveat, or question.
King et al. (2023) conducted a case report in Severe bioprosthetic mitral stenosis (n=1). Warfarin discontinuation was evaluated on Left atrial thrombus formation. A 55-year-old male developed a large left atrial thrombus 8 days after discontinuing warfarin in the setting of rapidly deteriorating bioprosthetic mitral valve stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: